In this paper we provide visual characterization of associative quasitrivial
nondecreasing operations on finite chains. We also provide a characterization
of bisymmetric quasitrivial nondecreasing binary operations on finite chains.
Finally, we estimate the number of functions belonging to the previous classes.Comment: 25 pages, 18 Figure

Chen, Xiequn

Du, Xin

Gupta, Neeraj

Hanley, Michael J.

Hou, Jian

Hua, Zhaowei

Jin, Jie

Ke, Xiaoyan

Li, Hongmei

Li, Junmin

Liu, Jing

Lu, Jin

Moreau, Philippe

Richardson, Paul G.

van de Velde, Helgi

Wang, Bingxia

Wang, Hui

Wu, Depei

Xu, Yan

Zhang, Xiaoquan

Zhou, Daobin

English

arXiv

Background: The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies.   Methods: Patients were randomized (1: 1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage, and prior proteasome inhibitor exposure. The primary endpoint was progression-free survival (PFS). In total, 115 Chinese patients were randomized (57 ixazomib-Rd, 58 placebo-Rd).   Results: At the preplanned final analysis for PFS, after median PFS follow-up of 7.4 and 6.9 months, respectively, PFS was improved with ixazomib-Rd versus placebo-Rd (median 6.7 vs 4.0 months; HR 0.598; p = 0.035). At the preplanned final analysis of overall survival (OS), after median follow-up of 20.2 and 19.1 months, respectively, OS was improved with ixazomib-Rd versus placebo-Rd (median 25.8 vs 15.8 months; HR 0.419; p = 0.001). On the ixazomib-Rd and placebo-Rd arms, respectively, 38 (67%) and 43 (74%) patients reported grade = 3 adverse events (AEs), 19 (33%) and 18 (31%) reported serious AEs, and 4 (7%) and 5 (9%) died on-study. The most frequent grade 3/4 AEs were thrombocytopenia (18%/7% vs 14%/5%), neutropenia (19%/5% vs 19%/2%), and anemia (12%/0 vs 26%/2%).   Conclusions: This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-Rd, with limited additional toxicity, in patients with RRMM.Millennium Pharmaceuticals Inc. of Takeda Pharmaceutical Company LimitedSCI(E)ARTICLE1

Institutional Repository of Peking University

Journal of Hematology & Oncology

Randomized, double-blind, placebo-controlled phase III study of ixazomib   plus lenalidomide-dexamethasone in patients with relapsed/refractory   multiple myeloma: China Continuation study

Abstract Background The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies. Methods Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage, and prior proteasome inhibitor exposure. The primary endpoint was progression-free survival (PFS). In total, 115 Chinese patients were randomized (57 ixazomib-Rd, 58 placebo-Rd). Results At the preplanned final analysis for PFS, after median PFS follow-up of 7.4 and 6.9 months, respectively, PFS was improved with ixazomib-Rd versus placebo-Rd (median 6.7 vs 4.0 months; HR 0.598; p = 0.035). At the preplanned final analysis of overall survival (OS), after median follow-up of 20.2 and 19.1 months, respectively, OS was improved with ixazomib-Rd versus placebo-Rd (median 25.8 vs 15.8 months; HR 0.419; p = 0.001). On the ixazomib-Rd and placebo-Rd arms, respectively, 38 (67%) and 43 (74%) patients reported grade ≥3 adverse events (AEs), 19 (33%) and 18 (31%) reported serious AEs, and 4 (7%) and 5 (9%) died on-study. The most frequent grade 3/4 AEs were thrombocytopenia (18%/7% vs 14%/5%), neutropenia (19%/5% vs 19%/2%), and anemia (12%/0 vs 26%/2%). Conclusions This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-Rd, with limited additional toxicity, in patients with RRMM. Trial registration ClinicalTrials.gov, NCT0156453

Jian Hou

Jie Jin

Yan Xu

Depei Wu

Xiaoyan Ke

Daobin Zhou

Jin Lu

Xin Du

Xiequn Chen

Junmin Li

Jing Liu

Neeraj Gupta

Michael J. Hanley

Hongmei Li

Zhaowei Hua

Bingxia Wang

Xiaoquan Zhang

Hui Wang

Helgi van de Velde

Paul G. Richardson

Philippe Moreau

Directory of Open Access Journals

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Visual characterization of associative quasitrivial nondecreasing
  operations on finite chains

Visual characterization of associative quasitrivial nondecreasing operations on finite chains

Abstract

Similar works

Full text

Available Versions

Institutional Repository of Peking University

Directory of Open Access Journals